These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26347330)

  • 1. The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.
    Jacquemin M; Toelen J; Schoeters J; van Horenbeeck I; Vanlinthout I; Debasse M; Peetermans M; Vanassche T; Peerlinck K; van Ryn J; Verhamme P
    J Thromb Haemost; 2015 Nov; 13(11):2087-92. PubMed ID: 26347330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.
    Jacquemin M; Toelen J; Feyen L; Schoeters J; Van Horenbeeck I; Vanlinthout I; Debasse M; Vanassche T; Peerlinck K; Verhamme P
    Int J Lab Hematol; 2018 Aug; 40(4):442-447. PubMed ID: 29573340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation.
    Božič Mijovski M; Malmström RE; Vene N; Antovic JP; Mavri A
    Sci Rep; 2021 Mar; 11(1):5920. PubMed ID: 33723299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole Blood Point-of-Care Testing for Incomplete Reversal With Idarucizumab in Supratherapeutic Dabigatran.
    Takeshita S; Tanaka KA; Sawa T; Sanda M; Mizobe T; Ogawa S
    Anesth Analg; 2020 Feb; 130(2):535-541. PubMed ID: 31490820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarucizumab for dabigatran overdose.
    Peetermans M; Pollack C; Reilly P; Liesenborghs L; Jacquemin M; Levy JH; Weitz JI; Verhamme P
    Clin Toxicol (Phila); 2016 Sep; 54(8):644-6. PubMed ID: 27224445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
    Glund S; Stangier J; van Ryn J; Schmohl M; Moschetti V; Haazen W; De Smet M; Gansser D; Norris S; Lang B; Reilly P; Kreuzer J
    Clin Pharmacokinet; 2017 Jan; 56(1):41-54. PubMed ID: 27317414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution.
    Grottke O; van Ryn J; Zentai C; Gan G; Honickel M; Rossaint R; Ten Cate H; Spronk HMH
    PLoS One; 2019; 14(1):e0209350. PubMed ID: 30615630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation.
    Bloemen S; Zwaveling S; Douxfils J; Roest M; Kremers R; Mullier F
    Thromb Res; 2018 Nov; 171():160-166. PubMed ID: 30316961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of dabigatran on select specialty coagulation assays.
    Adcock DM; Gosselin R; Kitchen S; Dwyre DM
    Am J Clin Pathol; 2013 Jan; 139(1):102-9. PubMed ID: 23270905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
    J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P
    Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis.
    Comuth WJ; Haase AM; Henriksen LØ; Malczynski J; van de Kerkhof D; Münster AB
    Scand J Clin Lab Invest; 2018; 78(1-2):1-5. PubMed ID: 29148292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
    Pollack CV; Reilly PA; van Ryn J; Eikelboom JW; Glund S; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Royle G; Sellke FW; Stangier J; Steiner T; Verhamme P; Wang B; Young L; Weitz JI
    N Engl J Med; 2017 Aug; 377(5):431-441. PubMed ID: 28693366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
    Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
    Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lupus-anticoagulant testing at NOAC trough levels.
    Ratzinger F; Lang M; Belik S; Jilma-Stohlawetz P; Schmetterer KG; Haslacher H; Perkmann T; Quehenberger P
    Thromb Haemost; 2016 Aug; 116(2):235-40. PubMed ID: 27075441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
    Norris S; Ramael S; Ikushima I; Haazen W; Harada A; Moschetti V; Imazu S; Reilly PA; Lang B; Stangier J; Glund S
    Br J Clin Pharmacol; 2017 Aug; 83(8):1815-1825. PubMed ID: 28230262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury.
    Sheikh-Taha M
    Am J Health Syst Pharm; 2019 Jan; 76(1):9-12. PubMed ID: 31381100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.